Drug search by name

Cancidas and Liver disease

Generic Name: caspofungin
Dosage Forms: injection, powder, lyophilized, for solution
Other Brand Names: Cancidas

Result of checking the interaction of drug Cancidas and disease Liver disease for safety when used together.

Check result:

Cancidas <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Caspofungin is primarily metabolized by the liver. In a single-dose study, plasma concentrations of caspofungin after a 70 mg dose in patients with mild hepatic impairment (Child-Pugh score 5 to 6) increased by approximately 55% compared to healthy control subjects, whereas patients with moderate hepatic impairment (Child-Pugh score 7 to 9) had an average plasma increase of 76%. In a 14-day multiple-dose study (70 mg on the first day followed by 50 mg daily), plasma concentrations in patients with mild hepatic impairment were increased modestly by about 19% to 25% on days 7 and 14 relative to healthy control subjects. No dosage adjustment is necessary in patients with mild hepatic impairment. For patients with moderate hepatic impairment, a reduced dosage of 35 mg/day is recommended following the initial 70 mg loading dose. There is no clinical experience with caspofungin in patients with severe hepatic impairment.

References: